Exploring gene knockout strategies to identify potential drug targets using genome-scale metabolic models

被引:0
作者
Abhijit Paul
Rajat Anand
Sonali Porey Karmakar
Surender Rawat
Nandadulal Bairagi
Samrat Chatterjee
机构
[1] Complex Analysis Group,Centre for Mathematical Biology and Ecology, Department of Mathematics
[2] Translational Health Science and Technology Institute,undefined
[3] NCR Biotech Science Cluster,undefined
[4] Jadavpur University,undefined
来源
Scientific Reports | / 11卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Research on new cancer drugs is performed either through gene knockout studies or phenotypic screening of drugs in cancer cell-lines. Both of these approaches are costly and time-consuming. Computational framework, e.g., genome-scale metabolic models (GSMMs), could be a good alternative to find potential drug targets. The present study aims to investigate the applicability of gene knockout strategies to be used as the finding of drug targets using GSMMs. We performed single-gene knockout studies on existing GSMMs of the NCI-60 cell-lines obtained from 9 tissue types. The metabolic genes responsible for the growth of cancerous cells were identified and then ranked based on their cellular growth reduction. The possible growth reduction mechanisms, which matches with the gene knockout results, were described. Gene ranking was used to identify potential drug targets, which reduce the growth rate of cancer cells but not of the normal cells. The gene ranking results were also compared with existing shRNA screening data. The rank-correlation results for most of the cell-lines were not satisfactory for a single-gene knockout, but it played a significant role in deciding the activity of drug against cell proliferation, whereas multiple gene knockout analysis gave better correlation results. We validated our theoretical results experimentally and showed that the drugs mitotane and myxothiazol can inhibit the growth of at least four cell-lines of NCI-60 database.
引用
收藏
相关论文
共 178 条
[1]  
Hornberg JJ(2006)Cancer: A systems biology disease Biosystem 83 81-90
[2]  
Bruggeman FJ(2018)Cancer statistics, 2018 CA Cancer J. Clin. 68 7-30
[3]  
Westerhoff HV(2017)Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study JAMA Oncol. 3 524-548
[4]  
Lankelma J(2017)Investments in cancer research awarded to UK institutions and the global burden of cancer 2000–2013: a systematic analysis BMJ Open 7 e013936-117
[5]  
Siegel RL(2017)Protein quality control dysfunction in cardiovascular complications induced by anti-cancer drugs Cardiovasc. Drugs Ther. 31 109-417
[6]  
Miller KD(2018)Genome scale metabolic models as tools for drug design and personalized medicine PLoS One 13 e0190636-176
[7]  
Jemal A(2012)Pharmacogenomics knowledge for personalized medicine Clin. Pharmacol. Ther. 92 414-570
[8]  
Fitzmaurice C(2014)Cancer systems biology: A peek into the future of patient care? Nat. Rev. Clin. Oncol. 11 167-207
[9]  
Maruthappu M(2015)Modeling cancer metabolism on a genome scale Mol. Syst. Biol. 11 817-558
[10]  
Fu HY(2011)How were new medicines discovered? Nat. Rev. Drug Discov. 10 507-14553